Using the Mounjaro injection to lose weight: what the decision really involves

What the Mounjaro injection actually does, and why that matters to your decision

Tirzepatide targets two separate hormone pathways at once. GLP-1 receptor activation reduces appetite and slows gastric emptying; GIP receptor activation adds a complementary effect on how the body processes energy. The combined action is why the SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the 15 mg dose over 72 weeks, figures that place it ahead of earlier single-pathway medicines.

That headline number is worth holding carefully. It represents an average across thousands of trial participants who also followed a reduced-calorie diet and increased their physical activity. Real-world results vary. People who respond well often describe a quieting of the persistent hunger that made calorie reduction so difficult before, not an absence of appetite entirely, but a noticeable shift. People who struggle tend to find the early gastrointestinal side effects harder to manage, or discover that their lifestyle cannot support the weekly injection routine.

Understanding this distinction matters to your decision because the injection is not a passive treatment. It works alongside dietary change and movement, not instead of them. If you want to explore how results vary across the evidence for Mounjaro's effectiveness, our dedicated page covers the trial data in more detail. If you are still weighing up whether this approach is right for you, our overview of Mounjaro weight loss injections explains how the treatment works from the ground up. The point here is that knowing what the mechanism actually does (rather than what the headlines promise) is the most honest starting point.

Eligibility: who the injection is licensed for, and what a prescriber checks

The UK licence for Mounjaro covers adults aged 18 and over with a BMI of 30 or higher, or a BMI from 27 upwards where at least one weight-related condition is present. Qualifying conditions include type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease. For some ethnic backgrounds (South Asian, Chinese, Middle Eastern, Black African or African-Caribbean) the BMI thresholds are typically set 2.5 kg/m² lower under UK clinical guidance.

A BMI figure alone does not determine whether treatment is appropriate. A prescriber also considers your health history, current medications, kidney and liver function, and whether any contraindications apply. Mounjaro is not recommended during pregnancy, breastfeeding or if you are trying to conceive. It is not licensed for under-18s. A personal or family history of medullary thyroid carcinoma or certain endocrine conditions requires specific discussion.

At nume, a GPhC-registered Independent Prescriber reads your consultation answers on the same day you submit them, a real clinician, not an automated system. Photo ID and a live weight check are part of that process. You can read more about what Mounjaro is used for, including its diabetes licence, if you want the full picture before you consult. The NICE technology appraisal TA1026 sets out the criteria used to guide NHS eligibility, which differs from the private licensed indications described above.

Practicalities that people underestimate before they start

The injection itself takes seconds. The pen is pre-filled and pre-dosed; the needle is fine. Most people find the technique straightforward after a first attempt, and a guide to choosing and rotating Mounjaro injection sites can help with that early learning curve. Rotate between the abdomen, thigh and upper arm each week to reduce local skin reactions.

Storage is the thing that catches people out. The pen must be kept refrigerated, between 2 °C and 8 °C. There is a limited window during which it can be held at room temperature, but the exact duration is set out in the Patient Information Leaflet rather than in general advice, because the window depends on storage conditions. If you travel frequently or do not have reliable fridge access, that is worth factoring in before you start, not after.

The gastrointestinal side effects (nausea, loose stools, constipation, reflux) are the most commonly reported. They are typically most noticeable in the first week or two after starting or after a dose increase, and they settle for most people. Eating smaller meals and staying well hydrated genuinely helps. A common question at this stage is where you tend to lose weight first on Mounjaro, and understanding how the body responds early on can help set realistic expectations alongside managing side effects. If you are managing a weekly routine with work and family commitments, knowing that the first dose or the first increase might bring a day or two of nausea (rather than encountering it as a surprise on a Tuesday morning before the school run) makes it easier to plan around.

How to weigh cost alongside clinical suitability

Private Mounjaro treatment is priced by dose and provider. Since Eli Lilly raised UK list prices in September 2025, market rates have typically ranged from around £149 to £375 per four-week pen, depending on strength. That range is worth understanding rather than ignoring, and the Mounjaro pricing page breaks down what legitimate private treatment costs actually include.

What those headline figures often omit: consultation fees, prescription charges, delivery costs and any support if side effects arise. At nume, the price shown on our treatment page covers all of that, consultation, prescription, tracked next-working-day delivery, and access to clinical support seven days a week. There are no subscriptions and no auto-renewals; each repeat order is reviewed by a prescriber before it is approved.

Cost should not be the primary filter for a prescription medicine. The more important questions are whether the supply chain is legitimate and whether clinical oversight is genuinely in place. The GPhC register entry for our pharmacy is publicly verifiable, and we encourage every patient to check it. If you have questions about the clinical process before committing, our FAQs cover the steps in plain language.